Key clinical point: The monoamine oxidase inhibitor phenelzine appears active and generally well tolerated in patients with biochemically recurrent, nonmetastatic, castrate-sensitive prostate cancer.
Major finding: A quarter of patients (5/20) achieved a prostate-specific antigen reduction of at least 30% from baseline, and two patients (10%) had a reduction of at least 50% from baseline. Serious toxicities included one case of grade 4 hypertension and two cases of grade 3 syncope.
Study details: A single-arm, phase 2 trial of 20 patients with biochemically recurrent, nonmetastatic, castrate-sensitive prostate cancer.
Disclosures: The study was funded by the USC-Taiwan Center for Translational Research and the National Cancer Institute. The authors disclosed financial affiliations with Amgen, Astellas, AstraZeneca, Bayer, and other companies.
Gross ME et al. Prostate Cancer Prostatic Dis. 2020 Mar 3. doi: 10.1038/s41391-020-0211-9.